Susquehanna International Group
EVOK

Susquehanna International Group’s Evoke Pharma EVOK Stock Holding History

Susquehanna International Group’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-451
Closed -$119K – 12725
2021
Q1 		$119K Buy
451
+205
+83% +$82K ﹤0.01% 11777
2020
Q4 		$91K Buy
246
+104
+73% +$53.6K ﹤0.01% 10537
2020
Q3 		$96K Buy
+142
New +$90.6K ﹤0.01% 9935

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WA
Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's EVOK Position: Q1 2021 in Review

Susquehanna International Group sold out of Evoke Pharma (EVOK) in Q1 2021, closing a stake of 520 shares — an estimated $208K sold.

Susquehanna International Group first reported a position in EVOK in Q4 2016 and held it in 7 quarters. The position peaked at $287K in Q3 2020. 25 funds tracked by Wall St. Rank hold EVOK as of Q1 2021.

  • Susquehanna International Group reported no remaining Evoke Pharma position as of Q1 2021 after selling out during the quarter.
  • Susquehanna International Group sold 520 Evoke Pharma shares in Q1 2021, an estimated $208K.
  • Susquehanna International Group first reported a position in Evoke Pharma in Q4 2016 and held it in 7 quarters.
  • Susquehanna International Group's Evoke Pharma position peaked at $287K in Q3 2020.
  • 25 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.